Secured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types
Conditions: Sarcoma; Ovarian Neoplasm; Central Nervous System Neoplasm; Thyroid Neoplasm; Carcinoma, Neuroendocrine; Neoplasms, Germ Cell and Embryonal Intervention: Drug: Pembrolizumab Sponsors: UNICANCER; National Cancer Institute, France; Ligue contre le cancer, France; Merck Sharp & Dohme Corp. Not yet recruiting - verified January 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials